(Q34253748)

English

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Lorenza Rimassa

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Nicola Personeni

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Filippo de Braud

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Armando Santoro

1 reference

ORCID Public Data File 2021

author name string

A Santoro

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

T Pressiani

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

G Citterio

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

G Rossoni

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

G Donadoni

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

F Pozzi

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

S Bozzarelli

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

G Rossoni

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

S Colombi

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

F Caligaris-Cappio

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Lambiase

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

C Bordignon

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

language of work or name

0 references

publication date

17 August 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

British Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

103

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

837-844

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858

0 references

Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Molecular therapy for the treatment of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Impaired angiogenesis in aminopeptidase N-null mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Efficiency of recombinant human TNF in human cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966632

6 July 2018

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605858

21 January 2018

Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605858

21 January 2018

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605858

21 January 2018

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605858

21 January 2018

Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605858

21 January 2018

Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20717115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6605858

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20717115%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34253748&oldid=1585680805"